US Bancorp DE Sells 67,064 Shares of Boston Scientific Co. (NYSE:BSX)

US Bancorp DE decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 15.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 376,673 shares of the medical equipment provider’s stock after selling 67,064 shares during the period. US Bancorp DE’s holdings in Boston Scientific were worth $21,775,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. BSW Wealth Partners boosted its position in shares of Boston Scientific by 2.3% during the 4th quarter. BSW Wealth Partners now owns 7,398 shares of the medical equipment provider’s stock valued at $428,000 after purchasing an additional 165 shares in the last quarter. Allstate Corp boosted its position in shares of Boston Scientific by 2.9% during the 4th quarter. Allstate Corp now owns 5,938 shares of the medical equipment provider’s stock valued at $343,000 after purchasing an additional 165 shares in the last quarter. Valley National Advisers Inc. boosted its position in shares of Boston Scientific by 2.3% during the 4th quarter. Valley National Advisers Inc. now owns 7,526 shares of the medical equipment provider’s stock valued at $435,000 after purchasing an additional 170 shares in the last quarter. Aveo Capital Partners LLC boosted its position in shares of Boston Scientific by 1.3% during the 4th quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider’s stock valued at $742,000 after purchasing an additional 171 shares in the last quarter. Finally, Whitaker Myers Wealth Managers LTD. raised its stake in Boston Scientific by 4.6% during the 4th quarter. Whitaker Myers Wealth Managers LTD. now owns 4,093 shares of the medical equipment provider’s stock worth $237,000 after buying an additional 179 shares during the period. Institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on BSX. TD Cowen upped their price target on Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research note on Thursday, March 7th. Evercore ISI increased their price objective on Boston Scientific from $72.00 to $78.00 and gave the stock an “outperform” rating in a research note on Thursday, April 25th. Oppenheimer increased their price objective on Boston Scientific from $58.00 to $68.00 and gave the stock a “market perform” rating in a research note on Thursday, February 1st. Argus increased their price target on Boston Scientific from $69.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, StockNews.com raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $75.41.

Boston Scientific Price Performance

NYSE:BSX opened at $75.63 on Friday. The firm has a market capitalization of $110.96 billion, a price-to-earnings ratio of 63.55, a P/E/G ratio of 2.60 and a beta of 0.77. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $76.25. The stock has a fifty day moving average of $70.61 and a 200 day moving average of $63.78. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.05. The company had revenue of $3.86 billion during the quarter, compared to analyst estimates of $3.68 billion. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. On average, research analysts expect that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In related news, EVP John Bradley Sorenson sold 17,587 shares of Boston Scientific stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the sale, the executive vice president now owns 50,638 shares of the company’s stock, valued at $3,620,617. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Boston Scientific news, EVP John Bradley Sorenson sold 17,587 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the sale, the executive vice president now owns 50,638 shares in the company, valued at $3,620,617. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $66.35, for a total value of $463,322.05. Following the sale, the executive vice president now owns 53,788 shares in the company, valued at approximately $3,568,833.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 67,616 shares of company stock valued at $4,819,057. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.